jRCT1031260160招募中不适用
Encorafenib and Binimetinib in BRAF-mutated Thyroid Cancer : a Real-world data Utilization Multi-center study (EMBLAZE study)
未提供0 个研究点目标入组 130 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Diagnosed with BRAF mutation-positive differentiated thyroid cancer* or anaplastic thyroid cancer
- •Other pathological types, excluding medullary thyroid cancer and anaplastic thyroid cancer, are also acceptable.
- •Newly initiated ENC+BIN combination therapy between May 17, 2024, and July 31, 2025 (Patients who have switched from the investigational drug to a commercially available medication are ineligible for enrollment)
- •Patients who are 18 years of age or older at the initiation of ENC+BIN combination therapy
- •For patients visiting the study site, written informed consent is obtained voluntarily from the patient after they have received a thorough explanation of the study and fully understood the information.
- •Additionally, the following a) through c) are permitted.
- •a) For patients who have difficulty writing, enrollment in this study is permitted based on the patient's oral consent, with a legally authorized representative providing written consent on their behalf.
- •b) For patients who are unable to provide consent themselves or who are deceased, enrollment is permitted if written informed consent is obtained from their legally authorized representative after providing an explanation.
- •c) If obtaining written consent from the research subject or their legally authorized representative is difficult, the reason for the difficulty must be documented in the medical records or equivalent. The study information should then be made publicly available to the research subjects and others, ensuring they have the opportunity to refuse participation (opt-out). Under this opt-out procedure, enrollment in the study is permitted.
排除标准
- •Patients who, at the start of ENC+BIN combination therapy, were prescribed a regimen other than 450 mg of ENC once daily orally and 45 mg of BIN twice daily orally (However, if adverse events occur before the second BIN dose on the first day of administration, leading to dose reduction or discontinuation, this is permitted.)
- •Having a history of multiple cancers or comorbidities within three years prior to the initiation of ENC+BIN combination therapy.
- •Participated in other interventional clinical trials or studies between the initial diagnosis of thyroid cancer and the start of ENC+BIN combination therapy. However, among patients who participated in interventional clinical trials or studies, those who received thyroid cancer treatment within the approved indications are eligible to participate in this study.
- •Patients who initiated ENC+BIN combination therapy at another hospital and have since been transferred to the study site.
- •Any other patients deemed unsuitable for enrollment in this study by the principal investigator or sub-investigators at the study site.
研究者
相似试验
招募中
2 期
Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer2024-515944-22-00Intergroupe Francophone De Cancerologie Thoracique119
招募中
2 期
eo- and adjuvant targeted therapy in BRAF-mutated anaplastic cancer of the thyroidBRAF V600-mutant anaplastic thyroid cancer10014713NL-OMON51864Academisch Medisch Centrum20
进行中（未招募）
不适用
A study of encorafenib and binimetinib given before and after surgery, compared with standard treatment after surgery, in patients with BRAF-mutant melanomaCancerMelanomaISRCTN14595136Cambridge University Hospitals NHS Foundation Trust45
进行中（未招募）
2 期
Encorafenib 联合 Binimetinib 治疗 BRAF V600E 突变的中国转移性非小细胞肺癌的 II 期研究未接受过 BRAF 和 MEK 抑制剂治疗，且既往未接受过治疗，或曾在转移情况下接受过一次系统性治疗的转移性的 BRAF V600E 突变型非小细胞肺癌（NSCLC）患者CTR20212962Pierre Fabre Medicament/
ALMAC Pharma Services Limited/
Pierre Fabre Medicament Production/
科文斯医药研发（北京）有限公司
进行中（未招募）
2 期
Encorafenib 联合 Binimetinib 治疗 BRAF V600E 突变的中国转移性非小细胞肺癌的 II 期研究Encorafenib 联合 Binimetinib 用于治疗未接受过 BRAF 和 MEK 抑制剂治疗，且既往未接受过治疗，或曾在转移情况下接受过一次系统性治疗的转移性的 BRAF V600E 突变型非小细胞肺癌（NSCLC）患者CTR20212961Pierre Fabre Medicament/
Catalent Pharma Solutions,LLC/
Pierre Fabre Medicament Production/
科文斯医药研发（北京）有限公司